Perrigo has acquired ScarAway, a leading OTC scar management brand, from Enaltus, LLC. The brand is expected to generate approximately $10 million in full, calendar year 2015 net sales or approximately $3 million for the remainder of the year.
Perrigo Chairman, President and CEO Joseph C. Papa commented, “While today’s acquisition of ScarAway@ is relatively small in comparison to other transactions we’ve recently announced, it serves as yet another example of our ability to execute on our ‘Base Plus Plus Plus’ strategy. We are excited to add this margin-enhancing asset to our already robust U.S. OTC portfolio and believe that by leveraging our unique distribution and customer network, Perrigo is well positioned to accelerate the growth of this brand.”
The acquisition is expected to be immediately accretive to Perrigo’s calendar year 2015 adjusted earnings per share and to immediately exceed Perrigo’s ROIC threshold.
